



PATENT
ATTORNEY DOCKET NO. 04843/113003

Certificate of Mailing: Date of Deposit: December 29, 2006

I hereby certify under 37 C.F.R. § 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Flora Katsikis
Printed name of person mailing correspondence

Flora Katsikis
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Teicher et al.	Art Unit:	1654
Serial No.:	10/646,063	Examiner:	Marcela M. Cordero Garcia
Filed:	August 22, 2003	Customer No.:	21559
Title:	CORTICOSTEROID CONJUGATES AND USES THEREOF		

Mail Stop RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicants submit the references listed on the enclosed Form PTO-1449, copies of which are enclosed, with the exception of U.S. patents and U.S. patent application publications. A copy of a search report from a corresponding international application is also enclosed.

Submission of this statement is not a representation that a search has been made, nor is the inclusion of information in this statement an admission that the information is material to patentability.


This statement is being filed before the receipt of a first Office action following the filing of a Request for Continued Examination under 37 C.F.R. § 1.114.

If there are any other charges or any credits, please apply them to Deposit Account No. 03-2095.

Respectfully submitted,

Date: December 29, 2006

Clark & Elbing LLP
101 Federal Street
Boston, MA 02110
Telephone: 617-428-0200
Facsimile: 617-428-7045



Paul T. Clark
Reg. No. 30,162
Jeffrey J. Ellison Reg. No. 51,649
for Paul T. Clark

Sheet 1 of 2

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	04843/113003
	Serial No.	10/646,063
	Applicant	Teicher et al.
	Filing Date	August 22, 2003
	Group	
	IDS Filed	December 29, 2006

U.S. PATENT DOCUMENTS			
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant
	5, 762, 918	Jun. 8, 1998	Thorpe et al.

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION				
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Translation (Yes/No)

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	04843/113003
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Serial No.	10/646,063
		Applicant	Teicher et al.
		Filing Date	August 22, 2003
		Group	
(37 C.F.R. § 1.98(b))	IDS Filed	December 29, 2006	

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
	Cortivo et al., "Antioxidant effects of hyaluronan and its alpha-methyl-prednisolone derivative in chondrocyte and cartilage cultures" <i>Seminars In Arthritis and Rheumatism</i> 26:496-501 1996.
	Hume et al., "In Vitro and In Vivo Characterization of Ocular Prednisolone Delivery Using Hyaluronate Ester Films and Prodrugs," <i>Pharmaceutical Research</i> , New York, 10:S200 1993.
	McLeod et al., "Glucocorticoid-Dextran Conjugates As Potential Prodrugs For Colon-specific Delivery: Hydrolysis in Rat Gastrointestinal Tract Contents" <i>J. Pharmacol. Sci., American Pharmacol. Asso.</i> 83:1284-1288 1994.
	Panarin et al., "Synthesis and Pharmacological Study Of Water-Soluble Polymer Derivatives Of Glucocorticoids," <i>Pharmacol. Chem. J.</i> 23:689-694 1989.

EXAMINER	DATE CONSIDERED
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	